BIOMAT Database Logo BIOMAT Database Logo

[Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders]. 1991

T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
1st Department of Internal Medicine, School of Medicine, Nagoya University.

Imipenem/cilastatin sodium (IPM/CS) and amikacin sulfate (AMK) were administered to 111 patients with severe infections complicating hematological disorders. Of the 111 patients, 93 were included in the present analysis of efficacy and 108 in that of safety. Twenty patients were evaluated as excellent, 37 as good, 8 as fair, and 28 as poor, with an overall rate of effectiveness of 61.3% (57/93). The synergistic interaction of IPM and AMK against clinical isolates (6 strains) was assessed in vitro using the checker board technique. Synergistic and additive effects were observed in 66.7% and 33.3% of the samples, respectively. Side effects were observed in 9 patients and abnormal laboratory test results in 2. These disappeared or returned to normal values after completion of therapy or discontinuation of IPM/CS and AMK. From the above findings, IPM/CS with AMK is considered to be a useful antibiotic combination for the treatment of severe infections complicating hematological disorders.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Clinical evaluation of imipenem/cilastatin sodium against severe infections complicating hematological disorders and solid tumors].
August 1991, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections].
September 1994, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Clinical evaluation of imipenem/cilastatin sodium against severe infections complicated with hematological disorders and solid tumors].
December 1989, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Clinical evaluation of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders].
December 1990, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Chemotherapy with imipenem/cilastatin for severe infections accompanied by malignant hematological disorders].
March 1993, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Clinical study of imipenem/cilastatin sodium in children with severe infections].
January 1990, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
Imipenem-cilastatin monotherapy in severe infections accompanying hematological malignancies.
January 1991, Japanese journal of medicine,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Clinical evaluation of imipenem/cilastatin sodium in infectious complications of hematological malignancies. Tohkai Research Group on Infections in Hematological Disorders].
August 1990, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
[Therapeutic evaluation of imipenem/cilastatin sodium for bacterial infections in patients with hematological diseases].
February 1992, The Japanese journal of antibiotics,
T Hotta, and Y Morishima, and H Saito, and Y Kodera, and N Hirabayashi, and M Tanaka, and H Mizuno, and H Suzuki, and Y Kato, and Y Morishita
Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders.
April 1992, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!